Boston Therapeutics today announces it will be making a presentation on a corporate update at the Livingston Securities Advanced and Nano Life Sciences Summit. The presentation is to be given by the President of Boston Therapeutics, Kenneth A. Tassey, Jr., on October 17, 2013, in New York City.
Mr. Tassey, Jr. will cover Boston Therapeutics’ product pipeline, including PAZ320. Other topics of discussion to be covered during the presentation include the company’s product to reduce post-meal glucose elevation as well as other corporate developments. The presentation will be available on Boston Therapeutics’ website: http://ir.stockpr.com/bostonti/overview.
Headquartered in Manchester, NH, Boston Therapeutics develops drugs that address diabetes using complex carbohydrate chemistry. Specifically the company is focused on development and commercialization of therapeutic molecules that address Type 2 diabetes. The company’s initial product pipeline consists of:
• PAZ320, a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion, reducing the amount of available glucose absorbed through the intestine.
• IPOXYN™, a glyco-protein based therapeutic agent using proprietary processes and patented technology. IPOXYN™ is an anti-necrosis drug that consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.
• OXYFEX™, a product that can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events.
The company is backed by a highly experienced and insightful management and scientific advisory team that has extensive expertise in complex carbohydrate chemistry, regulatory, and clinical development, with multiple submissions and approvals to U.S. Food and Drug Administration. Its executive management team has more than 100 years of combined experience.
For more information, visit www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment